Abstract: Described herein are dry immunogenic compositions and methods of freezing aluminum-containing vaccines such that when converted into a dried powder, the dry composition can be readily administered without loss of activity. Also described are methods of intranasal administering dry immunogenic compositions comprising antigens and aluminum adjuvants.

Abstract: Disclosed herein are derivatives of nucleobase analogues. The disclosed compounds have a nucleobase moiety and an omega-3 polyunsaturated fatty acid moiety, including pharmaceutically acceptable salt or prodrug thereof. Methods of using these compounds for the treatment of cancers such as pancreatic cancer are also disclosed.

Abstract: The invention generally encompasses a human-derived monoclonal antibody compositions and methods comprising a dry powder formulation for neutralizing SARS-CoV-2 and known variants thereof in a patient, comprising administering to the patient a dry powder formulation comprising the human-derived monoclonal antibody. The invention further encompasses compositions and methods comprising a dry powder formulation for treating or preventing COVID-19 and/or at least one symptom associated with COVID-19 in a patient, comprising administering to the patient a dry powder formulation comprising the human-derived monoclonal antib.

Abstract: Described herein are dry vaccine compositions and methods of freezing aluminum-containing vaccines such that when converted into a dried powder, the dry vaccine can be readily reconstituted to form a stable liquid vaccine without significant loss of activity.

Abstract: Dry powder compositions comprising biologically active antibodies or antibody fragments thereof are provided herein. In some aspects, the present disclosure includes methods of manufacturing these compositions and methods of using them in pulmonary administration or applying them to a tissue surface through a medical dry powder blower/sprayer/insufflator.

Abstract: Described herein is the use of thin film freeze drying methods with oil-in-water adjuvants to produce improved vaccine compositions. This approach solves several major problems associated with the emulsion-adjuvanted vaccines. Additionally, the developed dry powder compositions have the potential to be administered via non-invasive routes (such as intranasal, pulmonary, transcutaneous with or without microneedles) and be stored at ambient temperatures which significantly reduce the costs of vaccination programs.

Abstract: Described herein are dry powder compositions of liposomes, liposomal adjuvant or liposomal adjuvanted vaccines. Formulations containing a cryoprotectant can be converted to dry powders using, e.g., thin-film freeze-drying (TFFD). The composition may comprise a liposomal adjuvant, such as AS01B adjuvant, or also including an antigen, i.e., AS01B-adjuvanted vaccine compositions.

Abstract: Described herein are dry powder compositions of liposomes. Formulations containing a cryoprotectant can be converted to dry powders using, e.g., thin-film freeze-drying (TFFD) to obtain stabilized composition that show improved properties.

Abstract: Disclosed herein are nanoparticles comprising a lipid core comprising a sterol; and a complex comprising a cationic agent and a therapeutic agent, wherein the complex is encapsulated within the lipid core. Methods to produce the nanoparticle comprise: combining a cationic agent, a therapeutic agent, and a first water-immiscible solvent with a first aqueous solution, thereby forming a mixture comprising a complex comprising the cationic agent and the therapeutic agent; combining the mixture with a second waterim-miscible solvent, thereby forming an aqueous phase and an organic phase, and separating the organic phase comprising the complex; combining the organic phase comprising the complex with a sterol and a first water-miscible organic solvent; and dispersing the complex in a second aqueous solution to form a herein disclosed nanoparticle. Methods for treating a disease and for reducing nanoparticle burst rate are also disclosed.

Abstract: The present disclosure relates to functionalized gold carbene naphthoquinone compounds and salts thereof. In some aspects, these compounds can be used to treat cancer including cancers which are resistant to one or more other chemotherapeutic agents such as cisplatin or platinum chemotherapeutic agents. Also provided herein are pharmaceutical compositions comprising the gold carbene naphthoquinone compounds. The present disclosure also provides methods of preparing a cancer vaccine.

Abstract: Disclosed herein are derivatives of nucleobase analogues. The disclosed compounds have a nucleobase moiety and an omega-3 polyunsaturated fatty acid moiety, including pharmaceutically acceptable salt or prodrug thereof. Methods of using these compounds for the treatment of cancers such as pancreatic cancer are also disclosed.

Abstract: Dry powder compositions comprising biologically active polynucleotide molecules and methods for the manufacture of such dry powders are provided. In some aspects, dry powders of the embodiment comprise expressible or regulatory (e.g., siRNA) polynucleotide molecules complexed with nanoparticles. Dry powders comprising viable virus and bacteria are also provided.

Abstract: Disclosed herein are derivatives of nucleobase analogues. The disclosed compounds have a nucleobase moiety and an omega-3 polyunsaturated fatty acid moiety, including pharmaceutically acceptable salt or prodrug thereof. Methods of using these compounds for the treatment of cancers such as pancreatic cancer are also disclosed.

Abstract: Disclosed herein are nanoparticles for therapeutic and diagnostic use. The nanoparticles are designed to selectively accumulate in a tissue or organ of interest, and then release one or more therapeutically active or diagnostic agents. The nanoparticles include self-crosslinked therapeutic agents and therapeutic agents dispersed in a matrix.

Abstract: Described herein are dry immunogenic compositions and methods of freezing aluminum-containing vaccines such that when converted into a dried powder, the dry composition can be readily administered without loss of activity. Also described are methods of intranasal administering dry immunogenic compositions comprising antigens and aluminum adjuvants.

Abstract: Disclosed are nanoparticles comprising an active compound comprising a nucleobase analogue moiety covalently linked to an omega-3 polyunsaturated fatty acid moiety, or a pharmaceutically acceptable salt or prodrug thereof; a pegylated vitamin E compound; and at least one oil phase component. Also disclosed are methods for treating a subject with a disease comprising administering to the subject a therapeutically effective amount of the disclosed nanoparticles. The compositions and methods are useful for treating diseases such as tumors by delivering an array of active compounds including, for instance, 4-(N)-docosahexaenoyl 2?, 2?-difluorodeoxycytidine (DHA-dFdC) or other hydrophobic and/or lipophilic anti-cancer agents. The compositions and methods are further useful for delivering pharmaceutical and/or nutraceutical agents via numerous routes of administration. Methods of making the nanoparticles are also disclosed.

Abstract: Disclosed herein are nanoparticles comprising a lipid core comprising a sterol; and a complex comprising a cationic agent and a therapeutic agent, wherein the complex is encapsulated within the lipid core. Methods to produce the nanoparticle comprise: combining a cationic agent, a therapeutic agent, and a first water-immiscible solvent with a first aqueous solution, thereby forming a mixture comprising a complex comprising the cationic agent and the therapeutic agent; combining the mixture with a second waterim-miscible solvent, thereby forming an aqueous phase and an organic phase, and separating the organic phase comprising the complex; combining the organic phase comprising the complex with a sterol and a first water-miscible organic solvent; and dispersing the complex in a second aqueous solution to form a herein disclosed nanoparticle. Methods for treating a disease and for reducing nanoparticle burst rate are also disclosed.

Abstract: Disclosed herein are derivatives of nucleobase analogues. The disclosed compounds have a nucleobase moiety and an omega-3 polyunsaturated fatty acid moiety, including pharmaceutically acceptable salt or prodrug thereof. Methods of using these compounds for the treatment of cancers such as pancreatic cancer are also disclosed.

Abstract: Disclosed herein are derivatives of nucleobase analogs. The disclosed compounds have a nucleobase moiety and an omega-3 polyunsaturated fatty acid moiety, including pharmaceutically acceptable salt or prodrug thereof. Methods of using these compounds for the treatment of cancers such as pancreatic cancer are also disclosed.

Abstract: Described herein are dry vaccine compositions and methods of freezing aluminum-containing vaccines such that when converted into a dried powder, the dry vaccine can be readily reconstituted to form a stable liquid vaccine without significant loss of activity.